Notas de prensa

  • 18 de julio de 2006
  • 129

Amgen Update on Presentation Materials for Webcast of Second Quarter Financial Results

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--July 18, 2006--Amgen (Nasdaq:AMGN), the world´s largest biotechnology company, announced that as part of its efforts to continuously improve its investor communications, it intends to provide a slide presentation with its upcoming second quarter financial results conference call, scheduled for Thursday, July 20, 2006 at 2 p.m. Pacific Daylight Time. The slide presentation will be posted in the Investor section of the company´s Web site (www.amgen.com/investors) in advance of the company´s conference call. Amgen expects the slide presentation to be available on the Web site at or around the same time the company reports its second quarter financial results after the financial markets close.

About Amgen

Amgen discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science´s promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a broad and deep pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people´s lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.

CONTACT: Amgen, Thousand Oaks Dan Whelan, 805-447-5995 (media) Arvind Sood, 805-447-1060 (investors) SOURCE: Amgen

Destacadas

  • Nutricia impulsa la formación a médicos de familia sobre el deterioro cognitivo leve

    Ariana del Río García

    Nutricia impulsa la formación a médicos de familia sobre el deterioro cognitivo leve

    Leer más
  • Se presenta el primer análisis provisional del estudio PROSPER con mogamulizumab en pacientes con LCCT

    Ariana del Río García

    Se presenta el primer análisis provisional del estudio PROSPER con mogamulizumab en pacientes con LCCT

    Leer más
  • Roche revela su última innovación para la monitorización continua de glucosa (MCG) con capacidades predictivas en el 35º Congreso de la Sociedad Española de Diabetes (SED)

    Verónica SF

    Roche revela su última innovación para la monitorización continua de glucosa (MCG) con capacidades predictivas en el 35º Congreso de la Sociedad Española de Diabetes (SED)

    Leer más

Newsletter

Suscríbete para conocer las novedades del mundo farmacéutico y sanitario.

¿Qué es?

FarmaNews pone a disposición de los medios y departamentos de comunicación, un canal para publicar notas de prensa y convocatorias del mundo sanitario y farmacéutico.

Contacto

C/ Pau Clarís, 21, local 2
08780, Pallejà, Barcelona